Patents by Inventor Daniel B. Kim-Shapiro
Daniel B. Kim-Shapiro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230149732Abstract: A method for inhibiting device thrombosis for a patient may include circulating blood through an extracorporeal circuit coupled to the patient, infusing nitrite into the flow of blood such that the nitrite is bioactivated by red blood cells to form nitric oxide, and illuminating the flow of blood with far-red light to increase bioactivation of the nitrite by the red blood cells. A system for inhibiting device thrombosis for a patient may include an extracorporeal circuit configured to circulate a flow of blood, a nitrite infusion device coupled to the extracorporeal circuit and configured to infuse nitrite into the flow of blood, and one or more light sources disposed along the extracorporeal circuit and configured to illuminate the flow of blood with far-red light.Type: ApplicationFiled: November 17, 2022Publication date: May 18, 2023Inventors: Daniel B. Kim-Shapiro, James Eric Jordan, Elmira Alipour, Nadeem Wajih
-
Publication number: 20170281673Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.Type: ApplicationFiled: June 22, 2017Publication date: October 5, 2017Applicants: The Government of the U.S.A. as represented by the Sec. of the Dept. of Health and Human Services, Loma Linda University, Wake Forest UniversityInventors: Mark T. Gladwin, Alan N. Schechter, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Richard O. Cannon, III
-
Patent number: 9700578Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.Type: GrantFiled: January 5, 2015Date of Patent: July 11, 2017Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Acting through the Louisiana State University Health Sciences Center, The UAB Research Foundation, Loma Linda University, Wake Forest UniversityInventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
-
Patent number: 9675637Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.Type: GrantFiled: July 9, 2004Date of Patent: June 13, 2017Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, acting through Louisiana State University Health Sciences Center, The UAB Research Foundation, Loma Linda University, Wake Forest UniversityInventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Pluta, Edward H. Oldfield, Richard O. Cannon, III
-
Publication number: 20170087181Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.Type: ApplicationFiled: May 4, 2016Publication date: March 30, 2017Applicants: The Government of the U.S.A. as represented by the Secretary of the Department of Health and Human S, The UAB Research Foundation, Wake Forest UniversityInventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
-
Patent number: 9387224Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.Type: GrantFiled: February 28, 2012Date of Patent: July 12, 2016Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Wake Forest University, Loma Linda UniversityInventors: Mark T. Gladwin, Alan N. Schechter, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Richard O. Cannon, III
-
Publication number: 20150306183Abstract: Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.Type: ApplicationFiled: July 9, 2015Publication date: October 29, 2015Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Wake Forest UniversityInventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Mauro Tiso
-
Patent number: 9114109Abstract: Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.Type: GrantFiled: June 16, 2010Date of Patent: August 25, 2015Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, Wake Forest UniversityInventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Mauro Tiso
-
Publication number: 20150125553Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.Type: ApplicationFiled: January 5, 2015Publication date: May 7, 2015Applicants: The Government of the United States of America as represented by the Secretary of the Department of, The Board of Supervisors of Louisiana State Univer and Agricultural and Mechanical College, Acting t, The UAB Research Foundation, Loma Linda University, Wake Forest UniversityInventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
-
Patent number: 8980871Abstract: Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds preferentially react with cell-free OxyHb, as compared to OxyHb encapsulated in a red blood cell, and reacts with MetHb to form iron-nitrosyl Hb or nitrite bound MetHb. It has also been found that such compounds reduce cell-free Hb and hemolysis. Active compounds are also contemplated for use in combination therapies, for example, in combination with the administration of red blood cells and/or an agent that promotes hematopoiesis, or in combination with the administration of a nitric oxide donor.Type: GrantFiled: September 19, 2008Date of Patent: March 17, 2015Assignees: Wake Forest University Health Sciences, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Daniel B. Kim-Shapiro, S. Bruce King, Daniel A. Sweeney, Mark T. Gladwin
-
Patent number: 8927030Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.Type: GrantFiled: March 26, 2010Date of Patent: January 6, 2015Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
-
Publication number: 20140017342Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.Type: ApplicationFiled: September 17, 2013Publication date: January 16, 2014Applicants: The Government of the United States of America as represented by the Secretary of the Department of, Wake Forest University, University of Alabama at BirminghamInventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
-
Patent number: 8551536Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.Type: GrantFiled: August 29, 2008Date of Patent: October 8, 2013Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, University of Alabama at Birmingham, Wake Forest UniversityInventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
-
Publication number: 20120195983Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.Type: ApplicationFiled: February 28, 2012Publication date: August 2, 2012Inventors: Mark T. Gladwin, Alan N. Schechter, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Richard O. Cannon, III
-
Publication number: 20100323029Abstract: Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood.Type: ApplicationFiled: June 16, 2010Publication date: December 23, 2010Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Mauro Tiso
-
Publication number: 20100247682Abstract: It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.Type: ApplicationFiled: March 26, 2010Publication date: September 30, 2010Inventors: Mark T. Gladwin, Alan N. Schechter, David J. Lefer, Rakesh P. Patel, Christian J. Hunter, Gordon G. Power, Daniel B. Kim-Shapiro, Ryszard Marek Pluta, Edward H. Oldfield, Richard O. Cannon, III
-
Publication number: 20100247681Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.Type: ApplicationFiled: August 29, 2008Publication date: September 30, 2010Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
-
Publication number: 20100239692Abstract: Provided herein are methods of treating hemolysis by administering an active compound in an amount sufficient to treat said hemolysis. It has been found that nitroxyl donors or similar compounds preferentially react with cell-free OxyHb, as compared to OxyHb encapsulated in a red blood cell, and reacts with MetHb to form iron-nitrosyl Hb or nitrite bound MetHb. It has also been found that such compounds reduce cell-free Hb and hemolysis. Active compounds are also contemplated for use in combination therapies, for example, in combination with the administration of red blood cells and/or an agent that promotes hematopoiesis, or in combination with the administration of a nitric oxide donor.Type: ApplicationFiled: September 19, 2008Publication date: September 23, 2010Inventors: Daniel B. Kim-Shapiro, S. Bruce King, Daniel A. Sweeney, Mark T. Gladwin